InVivo Therapeutics Engages FDA With Second Product, A Novel Drug Releasing Hydrogel For Chronic Pain Treatment
06:00 EDT 2 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
InVivo Therapeutics Holdings Corp. (NVIV), a developer of
groundbreaking technologies for the treatment of spinal cord injuries
(SCI) and other neurological injuries, today announced a novel hydrogel
based product for the treatm...
Other Sources for this Article
InVivo Therapeutics
Bob Housler, Jr., 617-475-1529
bhousler@invivotherapeutics.com
More From BioPortfolio on "InVivo Therapeutics Engages FDA With Second Product, A Novel Drug Releasing Hydrogel For Chronic Pain Treatment"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
